Skip to content
Screener

Amgen AMGN G&A

G&A at other companies

Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$13.44M-44.8%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$7.29M+41.2%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$26.2M+85.4%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$12.65M+19.9%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$13.98M-0.7%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$28.24M+137%

Segments

By segment

See full
Reportable Segment$590M+6.5%

Other financials

Income statement

See full
Revenue$10.1B+9.5%
Gross profit$7.2B+17.4%
Operating income$3.5B+32.3%
Net income$2.4B+65.9%
EPS (diluted)$4.37+64.9%

Balance sheet

See full
Cash & equivalents$574.0M+5.9%
Total debt$57.3B+2.0%
Total equity$11.7B+57.4%
Total assets$95.6B+8.8%

Cash flow

See full
Operating cash flow$4.0B+75.5%
CapEx$513.0M+39.0%
Free cash flow$3.5B+82.6%

Valuation

See full
Market cap$220.64B+44.0%
Enterprise value$277.37B+32.8%
P/E25.2×+2.1×
P/S5.8×+1.4×

Profitability

See full
Gross margin69.5%+5.0pp
Operating margin30%+6.5pp
Net margin23%+4.0pp
FCF margin26.7%-3.7pp

Returns & leverage

See full
Return on equity91.5%-7.7pp
Debt / equity4.9×-2.7×
Current ratio1.4×+0.1×

FAQ

What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.